TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12830471
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no ribavirin therapy)
Study: 31174846
Drug: 0.6 mg
Normalized name: thymol 0.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 mg scopolamine
Study: 3149771
Drug: 1.2 mg
Normalized name: RNA 1.2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2 mg scopolamine
Study: 10953765
Drug: 1.8 mg
Normalized name: menthol 1.8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.8 mg scopolamine
Study: 10953765
Drug: 0.75 mg
Normalized name: propinox 0.75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75 mg subcutaneous physostigmine
Study: 7890463
Drug: Reduced Volume
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced Volume Taper (RVT)
Study: 7890463
Drug: Rest Only
Normalized name: Rest Simply
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rest Only Taper (ROT)
Study: 29229613
Drug: Acupuncture plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture plus auricular acupuncture (combination treatment)
Study: 26998845
Drug: Primary debulking
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary debulking surgery (PDS) followed by systemic adjuvant chemotherapy (arm A)
Study: 26998845
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy followed by interval debulking surgery (NACT/IDS) (arm B)
Study: 24363029
Drug: Adalimumab 160/80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab 160/80 (160 mg at weeks 0/2, then 40 mg every other week)
Study: 20007996
Drug: Filgrastim (FIL)
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Filgrastim (FIL) at a daily dose of 5 mug/kg
Study: 20007996
Drug: Pegfilgrastim (PEG)
Normalized name: Pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pegfilgrastim (PEG) at a single fixed dose of 6 mg
Study: 10799425
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (FO) supplementation (500 mg daily for nine weeks)
Study: 6667282
Drug: Beta-blockade (propanolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blockade (propanolol 160 mg/day)
Study: 8842111
Drug: Mefloquine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mefloquine (15 mg/kg)
Study: 31779926
Drug: Other medications
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other medications
Study: 22269152
Drug: Rosuvastatin 10
Normalized name: rosuvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 10 mg plus Fenofibrate 160 mg
Study: 20303247
Drug: Combination therapies
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapies including salmeterol qd or bid
Study: 17710485
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of prednisolone intravenously for 3 days (steroid group)
Study: 9452942
Drug: Donepezil (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil (up to 10 mg/day)
Study: 8578163
Drug: Lansoprazole (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole (60 mg every morning for 14 days) + Amoxicillin (500 mg oral suspension four times daily for 11 days)
Study: 8578163
Drug: Lansoprazole (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole (60 mg every morning for 14 days)
Study: 8578163
Drug: Lansoprazole +
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lansoprazole + Amoxicillin
Study: 31768768
Drug: Unfocused extracorporeal
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfocused extracorporeal shockwave therapy (3,000 electrohydraulic-generated shockwaves at 0.3 mJ/mm2)
Study: 26414670
Drug: Depression Medication
Normalized name: Nerve depressants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depression Medication Choice (DMC)
Study: 8314512
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of mebeverine hydrochloride into the sigmoid colon
Study: 2894246
Drug: Nipradilol (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nipradilol (9 mg)
Study: 27769675
Drug: 4 mL
Normalized name: ethanol 1.4 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mL liposomal bupivacaine (13.3 mg/mL)
Study: 27769675
Drug: 4 mL
Normalized name: ethanol 1.4 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mL 0.5% bupivacaine with 1:200,000 epinephrine
Study: 25439367
Drug: SMART (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: SMART (single budesonide‐formoterol inhaler as maintenance and reliever therapy)
Study: 25439367
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (fixed‐dose regimen with salbutamol as reliever)
Study: 22444829
Drug: Ranibizumab monotherapy
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ranibizumab monotherapy (0.5 mg, administered monthly)
Study: 22444829
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (verteporfin SF or RF)
Study: 20651204
Drug: Group A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A: 300 mg I/mL, 50 mL contrast material followed by a 20-mL saline bolus at 3.0 mL/s
Study: 20651204
Drug: Group B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B: 300 mg I/mL, 100 mL contrast material at 3.0 mL/s
Study: 29319646
Drug: Telenursing (weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telenursing (weekly phone calls for 12 weeks)
Study: 24954166
Drug: Morphine (10mg)
Normalized name: morphine 10 MG/ML
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine (10mg)
Study: 24075453
Drug: Canakinumab 5
Normalized name: Canakinumab
DrugBank: Canakinumab (DB06168)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Canakinumab 5 mg
Study: 24075453
Drug: Canakinumab 15
Normalized name: canakinumab 150 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canakinumab 15 mg
Study: 10088139
Drug: Pindolol 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pindolol 7.5 mg/day with TSD
Study: 7025683
Drug: Combined multidrug
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined multidrug chemotherapy
Study: 31819377
Drug: Combined 25‐G
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined 25‐G pars plana vitrectomy (PPV) with intravitreal dexamethasone implant (DXI)
Study: 31819377
Drug: Standard 25‐G
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard 25‐G PPV with ERM peeling only (control group)
Study: 15200998
Drug: Chemotherapy (C),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (C), 192 patients, three 3-weekly cycles of cisplatin/vindesine, mitomycin/ifosfamide/cisplatin, mitomycin/vinblastine/cisplatin or vinorelbine/cisplatin.
Study: 15200998
Drug: No chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: No chemotherapy (NoC), 189 patients.
Study: 9555596
Drug: Risperidone (RIS)
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Risperidone (RIS) 6.9 mg
Study: 9555596
Drug: Haloperidol and
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Haloperidol and Amitriptyline (HAL/AMI) 9 mg and 180 mg respectively
Study: 2839442
Drug: Conventional daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional daily radiation (5 x W) - 5 daily fractions of 2 Gy each to a total dose of 60 Gy in 6 weeks, protecting the spinal cord at 45 Gy.
Study: 2839442
Drug: Once‐a‐week radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once‐a‐week radiation (1 x W) - one weekly fraction of 5 Gy each to a total tumor dose of 60 Gy in 12 weeks, protecting the spinal cord at 30 Gy.
Study: 31763943
Drug: Polymyxin B
Normalized name: Polymyxin B
DrugBank: Polymyxin B (DB00781)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Polymyxin B 25 mg IV-RLP
Study: 31763943
Drug: Polymyxin B
Normalized name: Polymyxin B
DrugBank: Polymyxin B (DB00781)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Polymyxin B 50 mg IV-RLP
Study: 31763943
Drug: Polymyxin B
Normalized name: Polymyxin B
DrugBank: Polymyxin B (DB00781)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Polymyxin B 300 mg IV-RLP
Study: 25403578
Drug: FOLFOX4 (oxaliplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFOX4 (oxaliplatin 85 mg/m²)
Study: 25403578
Drug: FOLFOX7 (oxaliplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFOX7 (oxaliplatin 130 mg/m²) followed by FOLFIRI (irinotecan 180 mg/m²)
Study: 23598459
Drug: Diuretic adjustment
Normalized name: hydralazine hydrochloride / hydrochlorothiazide / reserpine Oral Tablet [Diuretic Ap-Es]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretic adjustment according to the AAD (algorithm de ajuste de diurético)
Study: 19514695
Drug: High-dose beta-lactam/beta-lactamase
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose beta-lactam/beta-lactamase inhibitor or second-/third-generation cephalosporin with azithromycin
Study: 19514695
Drug: Broad-spectrum antibiotics
Normalized name: Sentinel Spectrum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Broad-spectrum antibiotics for hospitalized patients
Study: 16675478
Drug: Uracil-tegafur (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uracil-tegafur (400 mg/m2 tegafur per day) for one year
Study: 16675478
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (surgery-alone group)
Study: 14722640
Drug: ICG‐PDR(0.5) with
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICG‐PDR(0.5) with dosage 0.5 mg/kg
Study: 14722640
Drug: ICG‐PDR(0.25) with
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICG‐PDR(0.25) with dosage 0.25 mg/kg
Study: 11803864
Drug: Melbrosia treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melbrosia treatment group
Study: 9557910
Drug: 0.5 mg.kg(‐1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg.kg(‐1) ephedrine intramuscularly
Study: 9557910
Drug: 0.25 mg.kg(‐1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg.kg(‐1) propofol intravenously
Study: 9557910
Drug: 0.1 ml.kg(‐1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 ml.kg(‐1) normal saline intravenously
Study: 7849542
Drug: Fluoride therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride therapy (mean, 23 mg elemental F daily for approximately 18 months)
Study: 7849542
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (38 osteoporotic females not receiving fluoride therapy)
Study: 11148800
Drug: Fluoride therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride therapy
Study: 3170393
Drug: amikacin 15.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: amikacin 15.0 mg/kg administered in a single daily dose
Study: 3170393
Drug: amikacin 11.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: amikacin 11.0 mg/kg administered in a single daily dose
Study: 3170393
Drug: amikacin 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: amikacin 7.5 mg/kg administered twice daily
Study: 20864423
Drug: Early enteral
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early enteral 5% glucose infusion (25 ml h(‐1) via jejunostomy tube initiated 6h after surgery)
Study: 20864423
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (peripheral parenteral nutrition for seven post-operation days)
Study: 20864423
Drug: Early enteral
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early enteral 5% glucose infusion
Study: 14594748
Drug: Donepezil (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil (5 mg/day for the first 28 days and 10 mg/day thereafter)
Study: 9707356
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg PETN
Study: 9707356
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg PETN
Study: 9707356
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg GTN
Study: 2650539
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg lovastatin twice daily for 6 weeks
Study: 2650539
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg lovastatin twice daily for 6 weeks
Study: 2650539
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg lovastatin twice daily for 6 weeks
Study: 2650539
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg lovastatin twice daily
Study: 2650539
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg lovastatin twice daily
Study: 2650539
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg lovastatin twice daily
Study: 2650539
Drug: Placebo for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for the first 6 weeks followed by stepped doses of lovastatin
Study: 31583989
Drug: Post-treatment remitted
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Post-treatment remitted DM+
Study: 31583989
Drug: Post-treatment remitted
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Post-treatment remitted DM-
Study: 31102328
Drug: High oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: High oxygen therapy (≥96% SpO2)
Study: 31102328
Drug: Low oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low oxygen therapy (90–92% SpO2)
Study: 26920551
Drug: Perceived needs
Normalized name: Plantago Seed
DrugBank: Plantago seed (DB11097)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perceived needs for substance treatment services
Study: 21980881
Drug: Deepwave treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deepwave treatment
Study: 9042992
Drug: Ondansetron (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (0.3 mg/kg)
Study: 9042992
Drug: Metoclopramide (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (0.3 mg/kg)
Study: 16353616
Drug: Fluoxetine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (60 mg/d)
Study: 16353616
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (Fluoxetine and Placebo)
Study: 30087555
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg fimasartan
Study: 30087555
Drug: Coadministration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coadministration of fimasartan and atorvastatin
Study: 25763853
Drug: Intra-articular injection
Normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injection of hyaluronic acid (HA) post-operatively
Study: 23270248
Drug: Kang'ai injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kang'ai injection with chemotherapy
Study: 12759389
Drug: Beta-carotene (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-carotene (25 mg)
Study: 8481254
Drug: Aspirin (ASA)
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin (ASA) with or without dipyridamole (D)
Study: 8481254
Drug: Anticoagulants (AC)
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulants (AC)
Study: 8481254
Drug: Aspirin (ASA)
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin (ASA) + Anticoagulants (AC)
Study: 8481254
Drug: Low (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low (100 mg) to medium (325 mg) daily aspirin dosage
Study: 8481254
Drug: Early postoperative
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early postoperative treatment (< or = 6 h)
Study: 8481254
Drug: Preoperative administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative administration of aspirin
Study: 29672392
Drug: Hyperoxygenated fatty
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperoxygenated fatty acids (HOFAs) treatment
Study: 26969090
Drug: Sunitinib 50
Normalized name: sunitinib 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib 50 mg per day orally for 54 weeks
Study: 26969090
Drug: Sorafenib 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib 400 mg twice per day orally for 54 weeks
Study: 18517133
Drug: Trimecaine 50
Normalized name: tricaine
DrugBank: Tricaine (DB11552)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimecaine 50 mg with 4 mg morphine administered epidurally in 8 hour intervals
Study: 18517133
Drug: Bupivacaine 0.25%
Normalized name: BUPIVACAINE 0.25%/NS INJ 400ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.25% and fentanyl 2 microg/ml administered at an infusion rate of 8 ml/h
Study: 18517133
Drug: Trimecaine with
Normalized name: tricaine
DrugBank: Tricaine (DB11552)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimecaine with morphine
Study: 10522523
Drug: Low-dose ACTH
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ACTH (0.005 mg/kg per day)
Study: 10522523
Drug: High-dose ACTH
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ACTH (0.025 mg/kg per day)
Study: 8748907
Drug: Chloral hydrate
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloral hydrate 70 mg/kg (group A)
Study: 8748907
Drug: Chloral hydrate
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloral hydrate 100 mg/kg (group B)
Study: 7025554
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 12‐50 microgram/min of salbutamol (Ventoline) and 4 mg orally at 4‐hour intervals
Study: 7025554
Drug: Fenoterol, 3‐4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoterol, 3‐4 microgram/min and subsequently 5 mg orally at 4‐hour intervals
Study: 28230742
Drug: GLU +
Normalized name: Glu
DrugBank: gamma-Glutamylcysteine (DB03408)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLU + FRU (1.2 g∙min‐1 glucose + 0.6 g∙min‐1 fructose)
Study: 28230742
Drug: GLU +
Normalized name: Glu
DrugBank: gamma-Glutamylcysteine (DB03408)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLU + SUC (0.6 g∙min‐1 glucose + 1.2 g∙min‐1 sucrose)
Study: 28230742
Drug: GLU (1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLU (1.8 g∙min‐1 glucose)
Study: 25912752
Drug: Trabectedin 3-hour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trabectedin 3-hour infusion (T3h)
Study: 25912752
Drug: Trabectedin 24-hour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trabectedin 24-hour infusion (T24h)
Study: 15513495
Drug: Continuous intraarticular
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intraarticular morphine 20 mg/mL, 0.5 mL plus ropivacaine 2 mg/mL, 100 mL; bolus 20 mL and 2 mL/hour from 24 to 72 hours postoperatively (group 2)
Study: 15513495
Drug: Double the
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double the dose of continuous intraarticular morphine and ropivacaine (4 mL/hour from 24 to 72 hours postoperatively) (group 3)
Study: 15513495
Drug: Standard postoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard postoperative analgesics (group 1)
Study: 15513495
Drug: Continuous intraarticular
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intraarticular morphine and ropivacaine (group 2 and group 3)
Study: 2883777
Drug: Vasodilators (including
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vasodilators (including nitrates and alpha-receptor blocking agents)
Study: 28110949
Drug: Oral acetazolamide
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral acetazolamide (500 mg) administration 1 hour preoperatively
Study: 28110949
Drug: Oral acetazolamide
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral acetazolamide (500 mg) administration 3 hours postoperatively
Study: 28110949
Drug: No acetazolamide
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No acetazolamide administration
Study: 21418045
Drug: Spinal hyperbaric
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal hyperbaric bupivacaine 7.5 mg
Study: 21418045
Drug: Spinal hyperbaric
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal hyperbaric bupivacaine 7.5 mg followed by epidural volume extension with saline 5 ml
Study: 21418045
Drug: Spinal hyperbaric
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal hyperbaric bupivacaine 10 mg without epidural volume extension
Study: 12136518
Drug: Breast conservation
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breast conservation therapy (BCT) with lumpectomy and radiation
Study: 12136518
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy followed by BCT
Study: 12136518
Drug: Addition of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Addition of chest wall and regional lymphatic irradiation to adjuvant systemic therapy
Study: 7977523
Drug: Nafarelin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nafarelin therapy (200 micrograms intranasally twice a day for 3 months)
Study: 7977523
Drug: Nafarelin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nafarelin therapy (200 micrograms intranasally twice a day for 6 months)
Study: 7977523
Drug: Nafarelin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nafarelin therapy (both 3 and 6 months)
Study: 7977523
Drug: Nafarelin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nafarelin therapy